Review articleA systematic review of currently available pharmacological neuroprotective agents as a sole intervention before anticipated or induced cardiac arrest☆
Introduction
Transient global cerebral ischaemia is a devastating event that is associated with great morbidity and prolonged and intensive medical treatment [1]. Transient global cerebral ischaemia can occur during asphyxiation, shock, brain injury, during extracorporeal circulation, and cardiac arrest. In certain clinical situations transient global cerebral ischaemia can either be anticipated or is even induced iatrogenically. The latter is the case during surgical repair of the thoracic aorta, complex congenital heart lesions and also during implantable cardiac defibrillator (ICD) testing in patients with drug resistant ventricular fibrillation. Furthermore, intraoperative hypothermia during cardiac or thoracic surgery with its proven neuroprotective effect is employed less frequently nowadays and is thus less often instituted during intraoperative emergencies so that pharmacologic neuroprotection remains the only alternative.
In the course of cardiac arrest, global cerebral blood flow is severely impaired with the consequent risk of ischaemic damage of brain cells. After reinstitution of the cerebral circulation, much greater damage may ensue. We could recently demonstrate that even brief recurrent cerebral hypoperfusions during implantation of ICD devices lead to NSE and S100 release post-operatively [2]. The magnitude of the rise of NSE, a serum markers of cerebral injury, was associated with the cumulative time in cardiac arrest.
Brain injury due to transient global cerebral ischaemia potentially could be mitigated by pharmacological means. A great number of neuroprotective pharmacological agents only prove effective when applied before the ischaemic insult and are less effective or not effective at all when given later in time, i.e. during ischaemia or reperfusion [3], [4]. Thus, we conducted a Medline search to find pharmacological agents that proved to be neuroprotective and can be administered before common clinical situations that result in cardiac arrest without the necessity to establish complex non-pharmacological measures.
As global and focal cerebral ischaemia have a substantially different pathophysiology, findings determined in hemispheric cerebral ischaemia cannot necessarily be applied to situations with global cerebral ischaemia [5]. This is underlined by the observation that ketamine was neuroprotective in focal ischaemia but not in global ischaemia in rats [6], [7]. Therefore, we restricted our literature search to studies investigating pharmacological measures applied prior to transient global cerebral ischaemia.
Section snippets
Methods and results
A Medline search was performed in June 2004 with the following combination of key words: “cerebral protection and global cerebral ischaemia”, “brain protection and global cerebral ischaemia”, “neuronal protection and global cerebral ischaemia”, “neuroprotection and global cerebral ischaemia”, “brain protection and cardiac arrest”, “neuronal protection and cardiac arrest”, “cerebral protection and cardiac arrest”, “neuroprotection and cardiac arrest” as well as “cerebral protection and
Discussion and conclusion
Unfortunately, despite its clinical relevance, only a limited number of studies investigated pharmacological neuroprotection when given as a pre-treatment before transient global cerebral ischaemia without the additional aid of non-pharmacological measures. Using a broad combination of terms listed in Section 2 we only came across 45 articles that dealt with this topic. As with all reviews that use specific terms to search the literature there is always a certain selection bias that prevents
References (60)
- et al.
Ascorbic acid is neuroprotective against global ischaemia in striatum but not hippocampus: histological and voltammetric data
Brain Res
(1999) - et al.
Intracerebroventricular propofol is neuroprotective against transient global ischemia in rats: extracellular glutamate level is not a major determinant
Brain Res
(2000) - et al.
The neuroprotective effects of gamma-vinyl GABA in transient global ischemia: a morphological study with early and delayed evaluations
Neurosci Lett
(1996) - et al.
Is chlormethiazol neuroprotective in experimental global cerebral ischemia? A microdialysis and behavioral study
Pharmacol Biochem Behav
(1997) - et al.
Neuroprotective effect of gamma-hydroxybutyrate in transient global cerebral ischemia in the rat
Eur J Pharmacol
(2000) - et al.
Neuroprotective effect of tiagabine in transient forebrain global ischemia: an in vivo microdialysis, behavioral, and histological study
Brain Res
(2002) - et al.
Failure of nimodipine to prevent brain damage in a global brain ischemia model in the rat
Resuscitation
(1993) - et al.
Neuroprotection by the novel calcium antagonist PCA50938, nimodipine and flunarizine, in gerbil global brain ischemia
Brain Res
(1997) - et al.
Ca2+ antagonist and protection of the brain against ischemia. Effects of nicardipine on free fatty acid liberation in the ischemic brain in rats
Surg Neurol
(1987) - et al.
Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study
Brain Res
(1995)
Polyunsaturated fatty acids induce ischemic and epileptic tolerance
Neuroscience
Neuroprotective effects of progesterone on damage elicited by acute global cerebral ischemia in neurons of the caudate nucleus
Arch Med Res
Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global cerebral ischemia in rats
Brain Res
Intravenous administration of magnesium is only neuroprotective following transient global ischemia when present with post-ischemic mild hypothermia
Brain Res
Occurrence of potentially detrimental temperature alterations in hospitalized patients at risk for brain injury
Mayo Clin Proc
Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain ischemia
Eur J Pharmacol
Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils
Neurosci Res
Effects of aniracetam on extracellular levels of transmitter amino acids in the hippocampus of the conscious gerbils: an intracranial microdialysis study
Neurosci Lett
Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition
Neurobiol Dis
CoQ10 fails to protect brain against focal and global ischemia in rats
Brain Res
Lost in translation: taking neuroprotection from animal models to clinical trials
Exp Neurol
The use-dependent sodium channel blocker mexiletine is neuroprotective against global ischemic injury
Brain Res
A pilot randomised trial of thrombolysis in cardiac arrest (The TICA trial)
Resuscitation
Brain function after resuscitation from cardiac arrest
Curr Opin Crit Care
Release of neuron-specific enolase and S100 after implantation of cardioverters/defibrillators
Crit Care Med
Neuronal protection and preservation of calcium/calmodulin-dependent protein kinase II and protein kinase C activity by dextrorphan treatment in global ischemia
J Cereb Blood Flow Metab
Ischemic cell death in brain neurons
Physiol Rev
Ketamine decreases plasma catecholamines and improves outcome from incomplete cerebral ischemia in rats
Anesthesiology
Differential effects of anesthetic agents on outcome from near-complete but not incomplete global ischemia in the rat
Anesthesiology
No barbiturate protection in a dog model of complete cerebral ischemia
Ann Neurol
Cited by (34)
Mitochondrial resuscitation after cardiac arrest
2021, ResuscitationAnesthetics, Cerebral Protection and Preconditioning
2013, Revista Brasileira de AnestesiologiaRegulation of Kv2.1 phosphorylation in an animal model of anoxia
2010, Neurobiology of DiseaseCitation Excerpt :NMDARs are essential to normal neuronal physiology, but their excessive activation by excess glutamate is thought to induce neuronal damage in many pathological conditions. As such, some reports have suggested that NMDAR antagonists have neuroprotective activities, but also that neuroprotective doses can cause various severe side-effects (Weigl et al., 2005). Memantine is a well-tolerated, low-affinity noncompetitive NMDAR antagonist that is presently clinically used as an anti-dementia agent (Parsons et al., 1999).
Lamotrigine attenuates cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits
2008, Surgical NeurologyTransient cerebral ischemia increases CA1 pyramidal neuron excitability
2008, Experimental Neurology
- ☆
A Spanish and Portuguese translated version of the Abstract and Keywords of this article appears at 10.1016/j.resuscitation.2004.11.004.